Gracell Biotechnologies Information

View Top Employees from Gracell Biotechnologies

As a member of the AstraZeneca Group, Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing novel autologous and allogeneic cell therapies for cancer and autoimmune diseases. Since its inception, Gracell has established a solid inhouse R&D system. Leveraging its proprietary FasTCAR and TruUCAR technology platforms and SMART CART™ technology modules, Gracell is researching new ways to address current challenges with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal T cell quality and barriers that limit their activity in solid tumors and autoimmune diseases.

Website	https://www.gracellbio.com/
Ticker	GRCL
Revenue	$106 million
Funding	$405.1 million
Employees	32 (25 on RocketReach)
Founded	2017
Address	Building 12 Block B Phase Ii Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park, Suzhou 215123, CN
Phone	+86 512 6262 6701
Industry	Biotechnology Research, Business Services General, Biotechnology, Business Services, Therapeutic Devices
Keywords	Cell Therapy, Cancer Treatment, Autologous Cell Therapy, Allogeneic Cell Therapy, Biopharmaceutical, Immunotherapy, Clinical Stage, Oncology, Autoimmune Disease Treatment, Cell Therapies, Regenerative Medicine, Biotechnology, Drug Development, Pharmaceutical Research, Clinical Trials, Healthcare, Medical Research, Pharmaceutical, Precision Medicine
Competitors	Johnson & Johnson, Roche, Novartis, AbbVie, Pfizer, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences, Receptos, a wholly-owned subsidiary of Celgene +45 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies